Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(1):29–35. doi: 10.1038/bjc.1996.6

p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry.

G M Horne 1, J J Anderson 1, D G Tiniakos 1, G G McIntosh 1, M D Thomas 1, B Angus 1, J A Henry 1, T W Lennard 1, C H Horne 1
PMCID: PMC2074293  PMID: 8554979

Abstract

We examined the reactivity of four p53-specific monoclonal antibodies--PAb 1801, p53-BP-12, D07 and CM1--on sections of formalin-fixed tissue collected from 245 breast carcinomas. Immunodetection of p53 varied between 37.6% and 46.6%. The greatest variation was observed among lobular carcinomas and low-grade tumors in which immunodetection varied between 8.3% and 27.3%. In contrast, immunodetection of p53 in invasive ductal carcinomas was subject to a lower degree of variability with between 40.6% and 49.7% of these tumours proving to be positive. In general, we found antibodies PAb 1801 and DO7 to be the most effective in immunolocalising p53. Immunodetection of p53 with each of the four antibodies was found to correlate strongly with tumour grade. In survival analysis, the results gained using antibody PAb 1801 proved to be of greatest statistical significance and to provide the strongest index of prognosis. A significant relationship was observed between immunodetection of p53 with each of the four antibodies and poor responsiveness to endocrine therapy. In addition, relationships were also observed between p53 immunostaining and tumour oestrogen receptor (ER) status as well as c-jun expression. We observed no correlation between abnormalities of the p53 and the Rb gene products or between elevated c-erbB-2 or epidermal growth factor receptor (EGFR) expression and immunodetection of p53.

Full text

PDF
29

Images in this article

31Figure 1
on p.31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 3;85(3):200–206. doi: 10.1093/jnci/85.3.200. [DOI] [PubMed] [Google Scholar]
  2. Baas I. O., Mulder J. W., Offerhaus G. J., Vogelstein B., Hamilton S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994 Jan;172(1):5–12. doi: 10.1002/path.1711720104. [DOI] [PubMed] [Google Scholar]
  3. Baker S. J., Fearon E. R., Nigro J. M., Hamilton S. R., Preisinger A. C., Jessup J. M., vanTuinen P., Ledbetter D. H., Barker D. F., Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989 Apr 14;244(4901):217–221. doi: 10.1126/science.2649981. [DOI] [PubMed] [Google Scholar]
  4. Banks L., Matlashewski G., Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986 Sep 15;159(3):529–534. doi: 10.1111/j.1432-1033.1986.tb09919.x. [DOI] [PubMed] [Google Scholar]
  5. Barbareschi M., Leonardi E., Mauri F. A., Serio G., Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol. 1992 Oct;98(4):408–418. doi: 10.1093/ajcp/98.4.408. [DOI] [PubMed] [Google Scholar]
  6. Barnes D. M. Breast cancer and a proto-oncogene. BMJ. 1989 Oct 28;299(6707):1061–1062. doi: 10.1136/bmj.299.6707.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barnes D. M., Dublin E. A., Fisher C. J., Levison D. A., Millis R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993 May;24(5):469–476. doi: 10.1016/0046-8177(93)90158-d. [DOI] [PubMed] [Google Scholar]
  8. Bártek J., Bártková J., Lukás J., Stasková Z., Vojtesek B., Lane D. P. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol. 1993 Jan;169(1):27–34. doi: 10.1002/path.1711690106. [DOI] [PubMed] [Google Scholar]
  9. Bártek J., Bártková J., Vojtesek B., Stasková Z., Lukás J., Rejthar A., Kovarík J., Midgley C. A., Gannon J. V., Lane D. P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991 Sep;6(9):1699–1703. [PubMed] [Google Scholar]
  10. Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D. P53 expression in breast cancer. Int J Cancer. 1988 Feb 15;41(2):178–183. doi: 10.1002/ijc.2910410204. [DOI] [PubMed] [Google Scholar]
  11. Corbett I. P., Henry J. A., Angus B., Watchorn C. J., Wilkinson L., Hennessy C., Gullick W. J., Tuzi N. L., May F. E., Westley B. R. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol. 1990 May;161(1):15–25. doi: 10.1002/path.1711610105. [DOI] [PubMed] [Google Scholar]
  12. Elledge R. M., Fuqua S. A., Clark G. M., Pujol P., Allred D. C., McGuire W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993;26(3):225–235. doi: 10.1007/BF00665800. [DOI] [PubMed] [Google Scholar]
  13. Galea M. H., Blamey R. W., Elston C. E., Ellis I. O. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207–219. doi: 10.1007/BF01840834. [DOI] [PubMed] [Google Scholar]
  14. Henry J. A., Piggott N. H., Mallick U. K., Nicholson S., Farndon J. R., Westley B. R., May F. E. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer. 1991 Apr;63(4):615–622. doi: 10.1038/bjc.1991.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Iwaya K., Tsuda H., Hiraide H., Tamaki K., Tamakuma S., Fukutomi T., Mukai K., Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res. 1991 Jul;82(7):835–840. doi: 10.1111/j.1349-7006.1991.tb02710.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jacquemier J., Molès J. P., Penault-Llorca F., Adélaide J., Torrente M., Viens P., Birnbaum D., Theillet C. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer. 1994 May;69(5):846–852. doi: 10.1038/bjc.1994.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992 May 8;256(5058):827–830. doi: 10.1126/science.1589764. [DOI] [PubMed] [Google Scholar]
  18. Lambkin H. A., Mothersill C. M., Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol. 1994 Jan;172(1):13–18. doi: 10.1002/path.1711720105. [DOI] [PubMed] [Google Scholar]
  19. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  20. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  21. Mackay J., Steel C. M., Elder P. A., Forrest A. P., Evans H. J. Allele loss on short arm of chromosome 17 in breast cancers. Lancet. 1988 Dec 17;2(8625):1384–1385. doi: 10.1016/s0140-6736(88)90584-3. [DOI] [PubMed] [Google Scholar]
  22. Martinazzi M., Crivelli F., Zampatti C., Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol. 1993 Sep;100(3):213–217. doi: 10.1093/ajcp/100.3.213. [DOI] [PubMed] [Google Scholar]
  23. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry J. A., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed] [Google Scholar]
  24. Mulligan L. M., Matlashewski G. J., Scrable H. J., Cavenee W. K. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5863–5867. doi: 10.1073/pnas.87.15.5863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Neville A. M. Are breast cancer axillary node micrometastases worth detecting? J Pathol. 1990 Aug;161(4):283–284. doi: 10.1002/path.1711610403. [DOI] [PubMed] [Google Scholar]
  26. Ostrowski J. L., Sawan A., Henry L., Wright C., Henry J. A., Hennessy C., Lennard T. J., Angus B., Horne C. H. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol. 1991 May;164(1):75–81. doi: 10.1002/path.1711640113. [DOI] [PubMed] [Google Scholar]
  27. Picksley S. M., Vojtesek B., Sparks A., Lane D. P. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 1994 Sep;9(9):2523–2529. [PubMed] [Google Scholar]
  28. Piggott N. H., Henry J. A., May F. E., Westley B. R. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J Pathol. 1991 Feb;163(2):95–104. doi: 10.1002/path.1711630204. [DOI] [PubMed] [Google Scholar]
  29. Poller D. N., Hutchings C. E., Galea M., Bell J. A., Nicholson R. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer. 1992 Sep;66(3):583–588. doi: 10.1038/bjc.1992.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sawan A., Lascu I., Veron M., Anderson J. J., Wright C., Horne C. H., Angus B. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J Pathol. 1994 Jan;172(1):27–34. doi: 10.1002/path.1711720107. [DOI] [PubMed] [Google Scholar]
  31. Sawan A., Randall B., Angus B., Wright C., Henry J. A., Ostrowski J., Hennessy C., Lennard T. W., Corbett I., Horne C. H. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol. 1992 Sep;168(1):23–28. doi: 10.1002/path.1711680105. [DOI] [PubMed] [Google Scholar]
  32. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  33. Spandau D. F. Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. Oncogene. 1994 Jul;9(7):1861–1868. [PubMed] [Google Scholar]
  34. Stephen C. W., Helminen P., Lane D. P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol. 1995 Apr 21;248(1):58–78. doi: 10.1006/jmbi.1995.0202. [DOI] [PubMed] [Google Scholar]
  35. Tiniakos D. G., Scott L. E., Corbett I. P., Piggott N. H., Horne C. H. Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J Pathol. 1994 Jan;172(1):19–26. doi: 10.1002/path.1711720106. [DOI] [PubMed] [Google Scholar]
  36. Trudel M., Mulligan L., Cavenee W., Margolese R., Côté J., Gariépy G. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1992 Dec;23(12):1388–1394. doi: 10.1016/0046-8177(92)90059-c. [DOI] [PubMed] [Google Scholar]
  37. Varley J. M., Brammar W. J., Lane D. P., Swallow J. E., Dolan C., Walker R. A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene. 1991 Mar;6(3):413–421. [PubMed] [Google Scholar]
  38. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  39. Vojtesek B., Bártek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992 Jul 6;151(1-2):237–244. doi: 10.1016/0022-1759(92)90122-a. [DOI] [PubMed] [Google Scholar]
  40. Walker R. A., Dearing S. J., Lane D. P., Varley J. M. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991 Nov;165(3):203–211. doi: 10.1002/path.1711650303. [DOI] [PubMed] [Google Scholar]
  41. Xu L., Chen Y. T., Huvos A. G., Zlotolow I. M., Rettig W. J., Old L. J., Garin-Chesa P. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol. 1994 Jun;3(2):83–92. doi: 10.1097/00019606-199406000-00004. [DOI] [PubMed] [Google Scholar]
  42. Yamashita H., Kobayashi S., Iwase H., Itoh Y., Kuzushima T., Iwata H., Itoh K., Naito A., Yamashita T., Masaoka A. Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res. 1993 Aug;84(8):871–878. doi: 10.1111/j.1349-7006.1993.tb02060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES